Friday 6 November 2026
Export XGN’s income statement to Excel — free account
Exagen Inc.
XGN Healthcare Diagnostics & Research
Exagen Inc.’s revenue for fiscal 2025 (year ended December 2025) was $66.6 million, up 19.7% from fiscal 2024.
- Revenue
- +15.9%
- EPS
- +38.1%
- Free cash flow
- +211.3%
- Total debt
- +6.44%
Quarter to June 2026, against a year earlier
5.80
1.80
−23.68%
Follow XGN
Alert me
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
Piotroski F-Score |
+8 more TTM periods Free account |
4 | 3 | 3 | 2 |
| (122.81%) | (147.85%) | (193.58%) | (113.82%) | ||
| (35.78%) | (38.85%) | (43.72%) | (34.19%) | ||
ROIC |
(103.05%) | (87.10%) | (50.19%) | (68.33%) | |
Return on Tangible Assets |
(40.34%) | (47.88%) | (53.59%) | (52.62%) | |
Average Days of Receivables |
63.66 | 59.51 | 84.19 | 63.67 | |
Free Cash Flow per Share |
(0.48) | (0.66) | (0.59) | (0.31) | |
Free Cash Flow |
(10.99) | (14.25) | (14.12) | (7.58) | |
Capital Expenditures |
(0.74) | (0.63) | (0.75) | (1.08) | |
| Other line items | |||||
Cash ROIC |
(13.93%) | (19.12%) | (23.29%) | (12.37%) | |
Accounts Receivable Turnover |
6.21 | 7.12 | 4.48 | 5.33 | |
Accounts Payable Turnover |
10.95 | 6.70 | 6.58 | 8.47 | |
Inventory Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Average Days of Payables |
50.88 | 54.57 | 53.26 | 55.07 | |
Days of Inventory on Hand |
0.00 | 0.00 | 0.00 | 0.00 | |
Tax Rate |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
9.67% | 0.00% | 8.85% | 8.71% | |
Selling, General and Administrative Expense of Revenue |
69.80% | 70.02% | 69.43% | 68.12% | |
Share Based Compensation of Revenue |
2.97% | 3.24% | 3.50% | 4.12% | |
Interest Coverage |
(3.51) | (3.26) | (2.80) | (2.58) | |
Operating CF/Net income |
0.54 | 0.68 | 0.66 | 0.34 | |
Depreciation/Fixed assets |
0.36 | 0.47 | 0.63 | 0.66 | |
Capex/Depreciation |
(0.27) | (0.19) | (0.18) | (0.25) | |
Revenue per Share |
2.77 | 3.09 | 2.87 | 2.94 | |
Operating CF per Share |
(0.45) | (0.63) | (0.56) | (0.27) | |
Capex per Share |
(0.03) | (0.03) | (0.03) | (0.04) | |
Capex to Sales |
0.01 | 0.01 | 0.01 | 0.02 |
Columns are period end dates · fundamentals updated 25 Oct 2026